BerGenBio ASA (BGBIOO.XC)

0.2683 0.0000 (0.00%) At close: 02:00PM BST

BerGenBio ASA

Møllendalsbakken 9
Bergen 5009
Norway
47 55 96 11 59
https://www.bergenbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 15

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Martin Olin	Chief Executive Officer	8.55M	N/A	1969
Mr. Rune Skeie	Chief Financial Officer	2.57M	N/A	1973
Ms. Cristina Oliva M.D.	Chief Medical Officer	4.88M	N/A	N/A
Graham Morell	Head of IR	N/A	N/A	N/A
Ms. Gayle M. Mills M.B.A	Chief Business Officer	N/A	N/A	1955
Dr. Akil Jackson	Medical Director	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.

Description

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.

Corporate governance

BerGenBio ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.